A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 4, 2013, Pages 939-943

  Long, Daniel D ^a   Frieman, Bryan ^a   Hegde, Sharath S ^a   Hill, Craig M ^a   Jiang, Lan ^a   Kintz, Samuel ^a   Marquess, Daniel G ^a   Purkey, Hans ^a   Shaw, Jeng Pyng ^a   Steinfeld, Tod ^a   Wilson, Michael S ^a   Wrench, Kevin ^a  

^a THERAVANCE INC   (United States)

Author keywords

Carbonic anhydrase (CA) II inhibitor; Dual pharmacology; Glaucoma; Intra ocular pressure (IOP); Multivalent; Prostaglandin F receptor (FP) agonist

Indexed keywords

CARBONATE DEHYDRATASE II; DORZOLAMIDE; PROSTAGLANDIN F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CORNEA PERMEABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLAUCOMA; NONHUMAN;

CARBONIC ANHYDRASE INHIBITORS; DRUG DISCOVERY; GLAUCOMA; HUMANS; MODELS, MOLECULAR; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN;

EID: 84872915972     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.12.058     Document Type: Article

References (29)

1. K. Zhang, L. Zhang, and R.N. Weinreb Nat. Rev. Drug Disc. 11 2012 541
2. H.A. Quigley Lancet 377 2011 1367
3. D.C. Musch, B.W. Gillespie, L.M. Niziol, P.R. Lichter, and R. Varma Ophthalmology 118 2011 1766
4. W.H. Morgan, and D.-Y. Yu Clin. Exp. Ophthalmol. 40 2012 388
5. J.J. Meyer, and S.D. Lawrence Curr. Opin. Ophthalmol. 23 2012 111
6. A.J. Lee, and I. Goldberg Expert Opin. Emerg. Drugs 16 2011 137
7. F. Carta, C.T. Supuran, and A. Scozzafava Expert Opin. Ther. Patents 22 2012 79
8. W.C. Stewart, J.A. Stewart, L.A. Nelson, and B. Kruft Eur. J. Ophthalmol. 18 2008 199
9. F. Aptel, C. Chiquet, and J.-P. Romanet Drugs 72 2012 1355
10. F. Aptel, and P. Denis Curr. Med. Res. Opin. 27 2011 1949
11. A.S. Khouri, T. Realini, and R.D. Fechtner Drugs Aging 24 2007 1007
12. R.M. Feldman, N.P. Bell, and K.S. Nagi Exp. Rev. Ophthalmol. 6 2011 151
13. ClinicalTrials.gov, NCT00767494.
14. M.R. Lesk, T. Koulis, F. Sampalis, J.S. Sampalis, and N.R. Bastien Ann. Pharm. 42 2008 498
15. A.P. Tanna, A.W. Rademaker, W.C. Stewart, and R.M. Feldman Arch. Ophthalmol. 128 2010 825
16. K. Lorenz, K. Rosbach, A. Matt, and N. Pfeiffer Clin. Ophthalmol. 5 2011 1745
17. N. Pfeiffer Graefes Arch. Clin. Exp. Ophthalmol. 249 2011 1065
18. D.D. Long, J.B. Aggen, B.G. Christensen, J.K. Judice, S.S. Hegde, K. Kaniga, K.M. Krause, M.S. Linsell, E.J. Moran, and J.L. Pace J. Antibiot. 61 2008 595
19. A.D. Hughes, K.H. Chin, S.L. Dunham, J.R. Jasper, K.E. King, T.-W. Lee, M. Mammen, J. Martin, and T. Steinfeld Bioorg. Med. Chem. Lett. 21 2011 1354
20. A.D. Hughes, A. McNamara, and T. Steinfeld Prog. Med. Chem. 51 2012 71
21. V.M. Krishnamurthy, G.K. Kaufman, A.R. Urbach, I. Gitlin, K.L. Gudiksen, D.B. Weibel, and G.M. Whitesides Chem. Rev. 108 2008 946
22. Software used for modelling work: LigPrep (3D ligand co-ordinate generation), Maestro (Protein preparation) and Glide (Docking), all from Schrodinger.
23. E.J. Corey, N.M. Weinshenker, T.K. Schaaf, and W. Huber J. Am. Chem. Soc. 91 1969 5675
24. Amine prepared via amide coupling of acetazolamide. HCl with N-Boc-glycine and subsequent Boc removal (i) N-Boc-glycine, HATU, DIPEA, DMF, 64%; (ii) TFA, DCM, 92%.
25. D. Seyferth, R.S. Marmor, and P. Hilbert J. Org. Chem. 36 1971 1379
26. J.C. Gilbert, and U. Weerasooriya J. Org. Chem. 47 1982 1837
27. H.C. Kolb, M.G. Finn, and K.B. Sharpless Angew. Chem., Int. Ed. 40 2001 2004
28. 2O, 66%.
29. http://labeling.pfizer.com/ShowLabeling.aspx?id=613 and http://www.merck.com/product/usa/pi-circulars/t/trusopt/trusopt-pi.pdf.